ONE-WAYOngoing theme · still written in the latest filings
China IND Approval and Clinical Development of CG001419 (TRK Degrader)
A development program for Cullgen’s TRK degrader CG001419, involving the Phase I clinical trial following IND approval in China, discussions with the U.S. FDA, and preparations for Phase II trials.
Companies1How many companies write about this.
Threads2One company can carry more than one thread here.